These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1273 related items for PubMed ID: 29072975

  • 21. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
    Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, von Bubnoff N, van Linde ME, Lai A, Prager GW, Campone M, Fasolo A, Lopez-Martin JA, Kim TM, Mason WP, Hofheinz RD, Blay JY, Cho DC, Gazzah A, Pouessel D, Yachnin J, Boran A, Burgess P, Ilankumaran P, Gasal E, Subbiah V.
    Lancet Oncol; 2022 Jan; 23(1):53-64. PubMed ID: 34838156
    [Abstract] [Full Text] [Related]

  • 22. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA.
    Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
    [Abstract] [Full Text] [Related]

  • 23. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.
    Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME.
    Thyroid; 2018 Jan; 28(1):79-87. PubMed ID: 29161986
    [Abstract] [Full Text] [Related]

  • 24. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
    Dummer R, Lebbé C, Atkinson V, Mandalà M, Nathan PD, Arance A, Richtig E, Yamazaki N, Robert C, Schadendorf D, Tawbi HA, Ascierto PA, Ribas A, Flaherty KT, Pakhle N, Campbell CD, Gusenleitner D, Masood A, Brase JC, Gasal E, Long GV.
    Nat Med; 2020 Oct; 26(10):1557-1563. PubMed ID: 33020648
    [Abstract] [Full Text] [Related]

  • 25. Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer.
    Jeon Y, Park S, Lee SH, Kim TH, Kim SW, Ahn MJ, Jung HA, Chung JH.
    Cancer Res Treat; 2024 Oct; 56(4):1270-1276. PubMed ID: 38453274
    [Abstract] [Full Text] [Related]

  • 26. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
    Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, Gasal E, Mookerjee B, Weber J, Flaherty KT.
    J Clin Oncol; 2018 Mar 01; 36(7):667-673. PubMed ID: 28991513
    [Abstract] [Full Text] [Related]

  • 27. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
    Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, Wang JR, Busaidy NL, Cabanillas ME.
    Thyroid; 2024 Mar 01; 34(3):336-346. PubMed ID: 38226606
    [Abstract] [Full Text] [Related]

  • 28. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
    Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, Gusenleitner D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Flaherty K, Larkin J, Robert C, Kefford R, Kirkwood JM, Hauschild A, Schadendorf D, Long GV.
    Lancet Oncol; 2020 Mar 01; 21(3):358-372. PubMed ID: 32007138
    [Abstract] [Full Text] [Related]

  • 29. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
    Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J.
    N Engl J Med; 2012 Nov 01; 367(18):1694-703. PubMed ID: 23020132
    [Abstract] [Full Text] [Related]

  • 30. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.
    Salama AKS, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT.
    J Clin Oncol; 2020 Nov 20; 38(33):3895-3904. PubMed ID: 32758030
    [Abstract] [Full Text] [Related]

  • 31. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
    Atkinson V, Sandhu S, Hospers G, Long GV, Aglietta M, Ferrucci PF, Tulyte S, Cappellini GCA, Soriano V, Ali S, Poprach A, Cesas A, Rodriguez-Abreu D, Lau M, de Jong E, Legenne P, Stein D, King B, van Thienen JV.
    Melanoma Res; 2020 Jun 20; 30(3):261-267. PubMed ID: 31895752
    [Abstract] [Full Text] [Related]

  • 32. A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
    Algazi AP, Moon J, Lao CD, Chmielowski B, Kendra KL, Lewis KD, Gonzalez R, Kim K, Godwin JE, Curti BD, Latkovic-Taber M, Lomeli SH, Gufford BT, Scumpia PO, Lo RS, Othus M, Ribas A.
    Cancer; 2024 May 15; 130(10):1784-1796. PubMed ID: 38261444
    [Abstract] [Full Text] [Related]

  • 33. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
    Saiag P, Robert C, Grob JJ, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Dutriaux C.
    Eur J Cancer; 2021 Sep 15; 154():57-65. PubMed ID: 34243078
    [Abstract] [Full Text] [Related]

  • 34. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.
    Schadendorf D, Robert C, Dummer R, Flaherty KT, Tawbi HA, Menzies AM, Banerjee H, Lau M, Long GV.
    Eur J Cancer; 2021 Aug 15; 153():234-241. PubMed ID: 34225229
    [Abstract] [Full Text] [Related]

  • 35. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
    Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, Grob JJ, Bondarenko I, Garbe C, Lebbe C, Larkin J, Chiarion-Sileni V, Millward M, Arance A, Mandalà M, Flaherty KT, Nathan P, Ribas A, Robert C, Casey M, DeMarini DJ, Irani JG, Aktan G, Long GV.
    Eur J Cancer; 2015 May 15; 51(7):833-40. PubMed ID: 25794603
    [Abstract] [Full Text] [Related]

  • 36. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.
    Long GV, Saw RPM, Lo S, Nieweg OE, Shannon KF, Gonzalez M, Guminski A, Lee JH, Lee H, Ferguson PM, Rawson RV, Wilmott JS, Thompson JF, Kefford RF, Ch'ng S, Stretch JR, Emmett L, Kapoor R, Rizos H, Spillane AJ, Scolyer RA, Menzies AM.
    Lancet Oncol; 2019 Jul 15; 20(7):961-971. PubMed ID: 31171444
    [Abstract] [Full Text] [Related]

  • 37. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
    Arıkan R, Telli TA, Demircan NC, Başoğlu T, Ercelep Ö, Atasoy BM, Özgüven S, Dane F, Yumuk PF.
    Curr Probl Cancer; 2021 Apr 15; 45(2):100668. PubMed ID: 33127167
    [Abstract] [Full Text] [Related]

  • 38. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.
    Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Long GV.
    J Clin Oncol; 2018 Dec 10; 36(35):3441-3449. PubMed ID: 30343620
    [Abstract] [Full Text] [Related]

  • 39. Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation.
    Teshima Y, Kizaki M, Kurihara R, Kano R, Harumiya M.
    Int J Clin Oncol; 2020 Oct 10; 25(10):1870-1878. PubMed ID: 32699976
    [Abstract] [Full Text] [Related]

  • 40. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
    Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S.
    J Clin Oncol; 2015 Dec 01; 33(34):4023-31. PubMed ID: 26392102
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 64.